Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,499Revenue (TTM) $M267Net Margin (%)-4.2Altman Z-Score5.0
Enterprise Value $M1,443EPS (TTM) $-0.3Operating Margin %-1.7Piotroski F-Score6
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-4.1Higher ROA y-yN
Price/Book6.610-y EBITDA Growth Rate %--Quick Ratio1.3Cash flow > EarningsY
Price/Sales5.95-y EBITDA Growth Rate %--Current Ratio1.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-79.7ROA % (ttm)-3.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-5.2Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M37.3ROIC % (ttm)-2.9Gross Margin Increase y-yY

Gurus Latest Trades with PCRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCRXMariko Gordon 2016-06-30 Add0.25%$33.73 - $64.56
($49.21)
$ 40.21-18%Add 11.79%1,076,724
PCRXRon Baron 2016-06-30 Add0.01%$33.73 - $64.56
($49.21)
$ 40.21-18%Add 247.61%56,351
PCRXMariko Gordon 2016-03-31 Add0.05%$45.36 - $76.79
($58.89)
$ 40.21-32%Add 1.57%963,184
PCRXRon Baron 2016-03-31 Add$45.36 - $76.79
($58.89)
$ 40.21-32%Add 25.44%16,211
PCRXMariko Gordon 2015-12-31 Reduce-0.24%$36.62 - $79.39
($57.34)
$ 40.21-30%Reduce -9.00%948,283
PCRXRon Baron 2015-12-31 Add$36.62 - $79.39
($57.34)
$ 40.21-30%Add 87.29%12,923
PCRXKen Fisher 2015-12-31 Add$36.62 - $79.39
($56.9)
$ 40.21-29%Add 4.15%6,197
PCRXMariko Gordon 2015-09-30 Add0.94%$40.95 - $70
($61.25)
$ 40.21-34%Add 56.02%1,042,012
PCRXGeorge Soros 2015-09-30 Sold Out -0.39%$40.95 - $70
($61.25)
$ 40.21-34%Sold Out0
PCRXRon Baron 2015-09-30 Buy $40.95 - $70
($61.25)
$ 40.21-34%New holding6,900
PCRXKen Fisher 2015-09-30 Add$40.95 - $70
($61.25)
$ 40.21-34%Add 23.96%5,950
PCRXGeorge Soros 2015-06-30 Buy 0.39%$65.78 - $92.39
($78.91)
$ 40.21-49%New holding531,800
PCRXRon Baron 2015-06-30 Sold Out -0.03%$65.78 - $92.39
($78.91)
$ 40.21-49%Sold Out0
PCRXMariko Gordon 2015-06-30 Add0.02%$65.78 - $92.39
($78.91)
$ 40.21-49%Add 1.19%667,877
PCRXJoel Greenblatt 2015-06-30 Sold Out -0.01%$65.78 - $92.39
($78.91)
$ 40.21-49%Sold Out0
PCRXMariko Gordon 2015-03-31 Reduce-0.12%$85.01 - $119.27
($101.46)
$ 40.21-60%Reduce -4.30%659,998
PCRXGeorge Soros 2015-03-31 Sold Out -0.084%$85.01 - $119.27
($101.46)
$ 40.21-60%Sold Out0
PCRXRon Baron 2015-03-31 Add0.01%$85.01 - $119.27
($101.46)
$ 40.21-60%Add 22.79%82,380
PCRXJoel Greenblatt 2015-03-31 Buy 0.01%$85.01 - $119.27
($101.46)
$ 40.21-60%New holding9,319
PCRXMariko Gordon 2014-12-31 Reduce-0.54%$86.02 - $107.8
($94.65)
$ 40.21-58%Reduce -15.33%689,628
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STACK DAVID MCEO and Chairman 2016-08-15Sell15,000$45.32-11.28view
Scibetta James SPresident 2016-08-15Sell25,000$45.21-11.06view
Riker Lauren BullaroVice President, Finance 2016-06-07Sell938$47.66-15.63view
Williams Kristen MarieCAO and General Counsel 2016-06-06Sell600$47.2-14.81view
Kronenfeld Mark A.Director 2016-06-06Sell900$46.95-14.36view
Brege LauraDirector 2016-06-06Sell1,000$46.95-14.36view
HASTINGS PAUL JDirector 2016-06-06Sell1,136$46.95-14.36view
STACK DAVID MCEO and Chairman 2016-04-15Sell25,000$64.14-37.31view
HASTINGS PAUL JDirector 2016-02-17Sell3,000$60-32.98view
Braunstein ScottSVP, Strategy & Corp. Dev. 2016-01-29Buy2,000$58.92-31.75view

Press Releases about PCRX :

Quarterly/Annual Reports about PCRX:

News about PCRX:

Articles On GuruFocus.com
Baron Funds Comments on Pacira Pharmaceuticals Aug 10 2016 
Baron Funds Comments on Pacira Pharmaceuticals Inc. May 19 2016 
Baron Funds Comments on Pacira Pharmaceuticals Inc. Feb 25 2016 
Mariko Gordon Nearly Doubles Stake in Forward Air Jan 04 2016 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Mariko Gordon's First Quarter Top Five May 15 2014 
Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 27 2011 
Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 16 2011 

More From Other Websites
Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults Aug 22 2016
Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value Aug 12 2016
PACIRA PHARMACEUTICALS, INC. Financials Aug 11 2016
Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss Aug 11 2016
Baron Funds Comments on Pacira Pharmaceuticals Aug 10 2016
Immune Design (IMDZ) Posts Wider-than-Expected Q2 Loss Aug 10 2016
Pacira Pharmaceuticals, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference Aug 09 2016
ETF’s with exposure to Pacira Pharmaceuticals, Inc. : August 8, 2016 Aug 08 2016
Pacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 Aug 05 2016
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US :... Aug 05 2016
Edited Transcript of PCRX earnings conference call or presentation 4-Aug-16 1:00pm GMT Aug 04 2016
Pacira Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today Aug 04 2016
Pacira reports 2Q loss Aug 04 2016
Pacira reports 2Q loss Aug 04 2016
PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2016
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results Aug 04 2016
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results Aug 04 2016
Q2 2016 Pacira Pharmaceuticals Inc Earnings Release - Before Market Open Aug 04 2016
New Research: Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously... Aug 01 2016
ETF’s with exposure to Pacira Pharmaceuticals, Inc. : July 21, 2016 Jul 21 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)